Found 24 Leukemia trials
A listing of Leukemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
The first purpose of this study is to test the safety of the addition of a drug called inotuzumab to the usual chemotherapy drugs used for adolescent young adults (ages 18-39). Inotuzumab is investigational and is not FDA-approved. Additionally,this study is to compare any good and bad effects of using …
Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints).
This phase III trial compares the effect of usual treatment of chemotherapy (Hyper CVAD) and steroids and a tyrosine kinase inhibitor (TKI) which are Dasatinib or Ponatinib and Blinatumomab to TKIs. B-cell acute lymphocytic leukemia.
This is a study for patients who have Acute Myeloid Leukemia who previously had Myelodysplastic Syndrome that were treated with Azacitidine or Decitabine.
The purpose of this study is to evaluate the efficacy and safety of mocravimod as an adjunctive and maintenance treatment in adult acute myeloid leukemia (AML) patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT).
This is a phase 1 study evaluating ziftomenib in combination with azacitidine and venetoclax, or standard induction therapy cytarabine/daunorubicin (7+3) or vyxeos chemotherapy for patients who have newly diagnosed or relapse refractory acute myeloid leukemia with KMT2A rearrangement or NPM1 mutation.
Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release. The primary purpose of a MAP is to provide access to product. NA - …
Please refer to Protocol Section 2 (Objectives and Endpoints) Please refer to Protocol Section 2 (Objectives and Endpoints) Please refer to Protocol Section 2 (Objectives and Endpoints)
This study will randomly assign hospitals to deliver either specialty palliative care or primary palliative care for patients with AML. Our site will provide participants with specialty palliative care. This study will enroll patients, their caregivers, and key informants (health care clinician or leader) to provide perspectives on palliative care.
The purpose of this study is understand changes in cognition, physical abilities, and quality of life of individuals receiving venetoclax-based chemotherapy.
